Capricor Therapeutics (NASDAQ: CAPR) faces a pivotal FDA advisory committee meeting on July 29, 2026, as the agency evaluates whether Deramiocel deserves approval for treating Duchenne muscular dystrophy. Shares plummeted 70% on the session, falling to $6.67, as FDA reviewers raised methodological concerns just days before the panel vote.
HOPE-3 Results: The Case for Approval
The Lancet published the Phase 3 HOPE-3 trial results on July 29, strengthening Capricor's regulatory submission ahead of the August 22 PDUFA decision. The trial enrolled 106 DMD patients in a randomized, double-blind, placebo-controlled study. Deramiocel met its primary endpoint, reducing the decline in upper-limb function by 54% compared with placebo. The therapy also demonstrated benefits related to cardiac function, a critical concern for DMD patients who typically die from heart complications.
"The HOPE-3 results are a landmark moment for the Duchenne community, demonstrating a significant benefit on skeletal muscle function alongside compelling data shown in cardiac function," said Dr. Craig McDonald, lead author and National PI of the HOPE-2 and HOPE-3 trials.
CEO Linda Marban framed the Lancet publication as validation of the therapy's clinical merit. "This is the same body of evidence that forms the foundation of our BLA and will be discussed at our Advisory Committee meeting. The publication reinforces our confidence in the strength and durability of these results," she said.
FDA Concerns: The SAP Dispute
The optimism faces a significant headwind. FDA reviewers released briefing documents on July 27 questioning whether the HOPE-3 trial provides convincing evidence that Deramiocel works. The core disagreement centers on which version of the Statistical Analysis Plan should govern the results.
The agency argues Capricor changed how it analyzed the data mid-trial, switching to a pre-specified SAP version 3.0. Under this revised plan, Deramiocel demonstrated the 54% benefit on upper-limb function. However, FDA staff indicated the trial failed to meet its original pre-specified primary endpoint under the initial analysis framework. The agency also flagged missed secondary endpoints, including left ventricular ejection fraction, a key measure of heart function.
This methodological dispute creates uncertainty around the approval decision. The advisory committee will weigh whether the SAP change invalidates the positive results or represents a legitimate protocol amendment justified by emerging data.
Trading Dynamics and Sentiment
CAPR shares were placed under a trading halt on July 29, classified under exchange T1 codes indicating pending material news. Retail sentiment on Stocktwits remained "extremely bullish" with elevated message volumes despite the stock's 77% decline year-to-date entering the session.
Multiple securities fraud investigations were announced following the FDA briefing document release. Law firms are examining whether Capricor adequately disclosed risks associated with the approval process to investors.
The elevated short interest of 15.58 million shares (10.79 days to cover) reflects significant bearish positioning ahead of the binary catalyst. Today's advisory committee outcome and the company's official statement will determine when trading resumes.
What Comes Next
The advisory committee meeting takes place July 29, 2026. Committee members will vote on whether Deramiocel's benefits outweigh its risks for DMD patients. The FDA considers this recommendation but retains final authority. The PDUFA target action date remains August 22, 2026, when the agency must issue a formal approval or rejection decision.
For investors tracking this binary event, Vantafin's calendar tool provides real-time updates on regulatory catalysts, while the CAPR quote page offers live pricing and volume data throughout the trading halt and beyond.